PS-05-011 The multimodal treatment for acute phase Peyronie Disease

Abstract

to present our experience with multimodal therapy for Peyronie Disease Retrospective data were collected since 2008 to 2017. The following features were evaluated at baseline and after treatment: age, duration of disease, erectile function (EF), erected penile curvature (EPC), stretched penile length (SPL). All patients were offered the same protocol including: 12 intralesional verapamil injections (IVIs); Oral therapy (OT): L-arginine 2 grams once and pentoxifylline 400 mg three times a day for 6 months; penile traction therapy. The adherence to each of the three component of multimodal treatment was evaluated . 177 individuals were considered. Depending on the grade of adherence our survey was divided into three groups. Group one: patients who only completed OT; Group two: men who accomplished OT and IVIs; Group three: patients who completed the entire protocol. 76 ,45 and 56 men were assigned to group one, two and three respectively. The mean age at the diagnosis was 59 (±8,4), 59,1 (±5,9) and 54,2 (±4,8) years, while the mean duration of the disease was 6,3(±3,4) , 4,8(±2,9) and 3,9 (±3,1) months in group one, two and three. The EPC before and after treatment was 24,2°(±9) and 23,7°(±8,9) in group one (p<0,36) ; 25,4° (±16,8) and 24,1° (±13,6) in group two (p<0,34) , 34,3° (±17,9) and 26,1° (±17,2) in group three (p<0,001).